Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05882487
EARLY_PHASE1

Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

View on ClinicalTrials.gov

Summary

This is a non-randomized, open label, dose-escalation study to evaluate the safety and efficacy of KL002 in the treatment of advanced primary Parkinson's disease. Condition or disease: Parkinson's Disease Intervention/treatment: Drug: KL002 Phase: NA

Official title: Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary Parkinson's Dissease

Key Details

Gender

All

Age Range

40 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

9

Start Date

2023-06-01

Completion Date

2026-06-30

Last Updated

2023-05-31

Healthy Volunteers

No

Interventions

GENETIC

KL002 injection solution

Neurosurgical delivery of KL002 to the brain

Locations (1)

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China